Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. is a biomedical company dedicated to developing next-generation T cell therapies that target mutated proteins (neo-antigens) in cancer. Neogene is developing a minimally invasive and scalable platform that will enable targeting of neo-antigens occurring in individual patients with fully personalized and genetically engineered “Designer T cells” that have been optimized to seek and destroy tumor cells based on neo-antigens.
Total raised: $110M

Investors 1

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
14.09.2020Series A$110M-Neogene Th...

Mentions in press and media 2

14.09.2020Neogene Th...Series A Financing led by EcoR...-Business W...venturebea...
14.09.2020Neogene Th...Neogene Therapeutics, Inc., a